Efficacy and safety of more intensive lowering of LDL cholesterol [2]

The Lancet

Volumn 377, Issue 9767, 2011, Pages 715-

  Giral, Philippe ^a   Moulin, Philippe ^b   Rosenbaum, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; CANCER RISK; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; BLOOD; CORONARY ARTERY DISEASE; HEART INFARCTION; NOTE;

CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION;

EID: 79952065059     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60262-6     Document Type: Letter

References (3)

1. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
2. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
3. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-16. (Pubitemid 47080485)